Angelina Jolie’s double mastectomy: Q&A

  • Posted: Tuesday, May 14, 2013 6:43 p.m.

Q: What did the procedure involve?

A: In double mastectomies, surgeons typically remove as much breast tissue as possible. In Jolie’s case, because she was having a reconstruction done shortly afterward, the doctors preserved the skin covering her breasts, inserting “fillers” where the breast tissue would have been, to keep the skin elastic. According to Jolie, she had implants put in nine weeks later.

Q: How many women have this faulty gene?

A: Only a small percentage of women have this same faulty gene, or a similar mutated version of a related gene, BRCA2. These mutations are most commonly found in women of Eastern European Jewish descent; one study found 2.3 percent of women in that group had the mutations – about five times higher than in the general population. Other ethnic groups, including the Norwegian, Dutch and Icelandic people, also have slightly higher rates of these mutations.

Q: How do these genes increase a woman’s risk of breast cancer?

A: The average woman has a 12 percent risk of developing breast cancer sometime during her life. In comparison, women who have inherited a faulty version of a breast cancer gene are about five times more likely to get breast cancer. In the U.S., about 5 to 10 percent of breast cancers are thought to be linked to harmful versions of the BRCA1 and BRCA2 genes.

Q: How can women find out if they have these gene mutations?

A: A genetic test using a blood test can usually detect these genes. In the U.S., there are no standard guidelines recommending women for BRCA1 or BRCA2 genetic testing. The test can cost several thousand dollars but may often be covered by insurance companies if women have risk factors that justify it. Women may be at higher risk for having a harmful mutation if they have close family members diagnosed with breast or ovarian cancer at an early age. Jolie says that her mother fought cancer for nearly a decade before dying at age 56.

Q: What does the test cost?

A: The test can cost several thousand dollars. According to Myriad Genetics, the sole provider of such tests in the U.S., 95 percent of patients have insurance that covers the test and the average out-of-pocket cost is $100. Myriad has a patient assistance program for those who aren’t covered by insurance.

Q: What other options might Jolie have had?

A: Doctors would likely have suggested earlier screening tests, including mammograms or MRIs, but those would only help them spot breast cancer earlier, not prevent it. They might also consider using breast cancer drugs preventively, though trials into their long-term use are still ongoing. “This is not a decision that people take lightly,” said Dr. Emma Pennery, clinical director at the British charity, Breast Cancer Care. “You cannot decide to have a double mastectomy next week.”

Q: How relevant is Jolie’s decision to other women?

A: For most women, genetics will not play a big part in whether or not they get breast cancer. “The majority of women considering their breast cancer risk should focus on things like a healthy lifestyle, eating a balanced diet, keeping a healthy weight and not drinking too much alcohol,” said Dr. Peter Johnson, chief clinician at Cancer Research U.K. About one third of breast cancer cases in Britain are largely tied to modifiable lifestyle risk factors.

But for women with a similar genetic risk to Jolie, it’s possible her decision to go public about her double mastectomies will prompt more procedures. “It’s a very empowering message that women are not helpless when faced with a genetic cancer risk,” Johnson said.

Comments { }

Commenting rules: Do not post offensive, racial or violent messages. Responsibility for the statements posted lies with the commenter, not www.aikenstandard.com. Click 'report abuse' for any comments that you feel should be removed from the site. However, www.aikenstandard.com is not obligated to remove any comment posted on the site. Moderators do not have the ability to edit comments. Read the terms of use.